Despite the indispensability of PLK1 in mutant KRAS‐driven cancer (Luo et al, 2009), efficacy of PLK1 inhibitors as monotherapy has been thwarted by poor response rates of patients (Sebastian et al, 2010; Gutteridge et al, 2016). Here, KRAS is linked to cancer.